KalVista Pharmaceuticals (KALV) Appoints Laurence Reid to its Board

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success.

“I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors,” said Ben Palleiko, Chief Executive Officer of KalVista. “His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization.”

“I am excited to join the KalVista Board at this transformational time in the Company’s journey,” said Dr. Reid. “I believe sebetralstat has the potential to significantly improve the lives of people living with hereditary angioedema. I look forward to working with the team on the Company’s transition to a commercial organization and supporting its long-term growth.”

Dr. Reid was the CEO of Decibel Therapeutics prior to its acquisition by Regeneron Pharmaceuticals in September 2023. Previously, Dr. Reid served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery opportunities. Before Third Rock, Dr. Reid was Chief Executive Officer of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. He also served as Chief Business Officer of Alnylam Pharmaceuticals and Ensemble Therapeutics and held senior leadership roles at Millennium Pharmaceuticals. Dr. Reid currently serves as the chair of the board of Broken String Biosciences, is a board member of Garuda Therapeutics and The Possible Zone and serves as a board advisor to Life Science Cares and Mount Auburn Hospital.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Nu Skin EVP of global sales takes medical leave
• Kimbell Royalty closes $221.2M mineral rights acquisition